A systematic review and meta‐analysis of these four CKD outcomes trials reported that SGLT2 inhibitor use reduced kidney disease progression by 38% (RR 0.62; 95% CI 0.56–0.69) with similar RRs in participants with and without diabetes [65]. Here, SLC5A2 is linked to diabetes mellitus.